Japan Diabetes Market

Japan Diabetes Market Size:

The Japan diabetes market size reached US$ 5.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.3 Billion by 2032, exhibiting a growth rate (CAGR) of 3.3% during 2024-2032. The market is primarily driven by the growing geriatric population, increased prevalence of diabetes, enhanced healthcare spending with supportive government initiatives, and technological advancements in treatment options.

Japan Diabetes Market Analysis:

• Major Market Drivers: The rising prevalence of diabetes in Japan due to the changing lifestyles and an aging population represents a major growth-inducing factor. In addition, recent research indicates that the diabetic patient population is still growing, which is increasing the Japan diabetes market demand. Besides, the government has funded and executed several health initiatives to enhance the treatment and management of diabetes. These include diabetes treatment subsidies and public health initiatives that encourage market expansion.
• Key Market Trends: Advanced diabetes care technology like insulin pumps and continuous glucose monitors (CGMs) are becoming more popular. Moreover, the market is witnessing a trend toward individualized treatment plans and customized medicines, which is driven by greater research into genetic variables and unique patient demands to deliver more efficient and specialized diabetes management solutions.
• Competitive Landscape: The Japanese diabetes market is dominated by giant international pharmaceutical and medical device businesses, as their wide range of products and cutting-edge technology help them to stay competitive. Additionally, Japanese companies are offering innovations and customized solutions specific to the requirements of Japanese patients.
• Challenges and Opportunities: Challenges in the market include stringent regulatory regulations and protracted approval procedures for novel diabetic therapies. On the other hand, the growing geriatric population offers substantial opportunities for the development of diabetes treatment and management programs specifically designed for this demographic. Besides, the development of digital health technologies, such as telemedicine and mobile health apps, creates new possibilities for better patient engagement and diabetes management.

Japan Diabetes Market Trends:

Rising Diabetes Prevalence

The growth of the diabetes market in Japan is driven by the rising incidence of diabetes. According to the International Diabetes Federation (IDF) reports, with 93,187,400 individuals in the country as of 2021, the prevalence rate of diabetes is 11.8% or 11,004,999 cases among adults. As a result, the market is expanding due to the increasing need for complete diabetes care solutions, which include cutting-edge drugs and monitoring equipment. Moreover, pharmaceutical businesses and healthcare professionals are compelled by the increasing number of patients to create and offer a wide array of treatment alternatives that address the diverse demands of their patients. In addition, the rise in diabetes cases has increased diabetes-specific healthcare services that attempt to enhance patient outcomes and quality of life. Hence, this trend has propelled the sales of anti-diabetic medications and boosted the market for innovative glucose monitoring technologies that promise more accurate and user-friendly options, thus creating a positive Japan diabetes market outlook.

Growing Geriatric Population

As reported by the Ministry of Internal Affairs and Communications, Japan's elderly population, those aged 65 and above, reached 36,227 thousand as of September 15, 2023. Moreover, the proportion of seniors in the overall population increased by 0.1% points to 29.1%, the highest percentage ever recorded. Additionally, the elderly are more susceptible to type 2 diabetes, which escalates the need for specialized diabetes management programs and products. This change in the population motivates healthcare organizations and clinicians to concentrate on the treatment of geriatric diabetes, resulting in advancements in medication therapy, nutritional guidance, and patient education customized to the needs of the geriatric population. Besides, the aging population influences several services and products that are in demand, offer simple use and low invasiveness, which are ideal for senior patients, and increase the volume of diabetic treatments that are necessary.

Supportive Government Initiatives and Healthcare Spending

The diabetes market is driven by the government of Japan's aggressive approach to healthcare spending, which includes a sizeable budget for treating chronic illnesses like diabetes. According to Frontiers, in 2020, Japan's national medical spending skyrocketed to 43 Trillion yen (304 Billion USD), nearly doubling from past figures since 1990. This indicates an increase in the nation's gross domestic output from 4.6% to 8.0%. In addition, the government ensures that enough money is spent on diabetes care, which makes treatments more accessible and reasonably priced. The foundation of diabetes care is being improved due to these programs, which cover everything from sophisticated treatment choices to primary prevention. In addition, numerous government initiatives concentrated on screenings and public health campaigns to lower the prevalence of diabetes while improving its management at the community level are influencing the market growth. Hence, these comprehensive health policies support Japan diabetes market growth by increasing awareness and early detection while integrating advanced diabetes care into the public health system.

Japan Diabetes Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts for the period 2024-2032. Our report has categorized the market based on segment.

Breakup by Segment:

• Oral Antidiabetics
• Insulin
   

Insulin accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the segment. This includes oral antidiabetics, and insulin. According to the report, insulin represented the largest segment.

Insulin reflects a substantial portion of the market share due to the increasing prevalence of diabetes among the aging population and the rising adoption of insulin therapies for effective glucose management. Additionally, Japan's healthcare system, renowned for its efficiency, extensively supports diabetes care, enabling widespread access to insulin treatments. Moreover, the market benefits from advancements in insulin formulations and delivery systems, which enhance patient adherence and outcomes. Besides, the Japanese government's proactive health initiatives aim to improve diabetes awareness and screening, further driving the demand for insulin. Furthermore, this segment's growth is also fueled by collaborations between domestic pharmaceutical companies and global diabetes care leaders, aiming to innovate and expand the availability of cutting-edge insulin solutions tailored to the unique needs of Japanese patients. Hence key players are introducing advanced product variants to meet these needs. For instance, in March 2023, in Tokyo Japan, and Taipei, Taiwan, Health2Sync, announced the recent update of its Health2Sync App now including insulin data from the Mallya Cap, a connected device for insulin pens created by Biocorp and marketed in Japan by Novo Nordisk. This collaboration introduces the world's first integration of this type of data and is designed to aid patients undergoing insulin treatment by tracking various health metrics, such as insulin injection records. Due to these innovations, the Japan diabetes market forecast states that insulin segment will continue to dominate the market.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have been provided. 
• At present, key players in the market are actively enhancing growth through strategic collaborations, advanced research and development (R&D) initiatives, and educational programs to improve diabetes management. Additionally, companies like Novo Nordisk and Sanofi are investing heavily in the development of next-generation insulin therapies and glucose monitoring systems tailored to meet the specific needs of Japanese patients, thus accounting for the Japan diabetes market share. These firms collaborate closely with local healthcare providers to ensure broad distribution and integration of their products into daily medical practice. Furthermore, these market leaders support extensive patient education campaigns to increase awareness about diabetes symptoms, treatment options, and lifestyle adjustments necessary for effective disease management. These comprehensive strategies strengthen their market position and significantly contribute to improving patient outcomes in Japan. For instance, on 29 March 2023, Maryland, Astellas Pharma Inc. announced its partnership with Roche Diabetes Care Japan Co., Ltd. This partnership focuses on the development and commercialization of the globally recognized Accu-Chek Guide Me blood glucose monitoring system, noted for its high accuracy, in conjunction with BlueStar®*1. BlueStar, an FDA-approved digital health solution for managing diabetes, is developed by Welldoc, Inc. and is available in the U.S. and Canada. Astellas and Welldoc are collaboratively advancing BlueStar's development in Japan. Astellas plans to seek regulatory approval and reimbursement for this integrated medical product in the future.

Japan Diabetes Market News:

• 18 April 2023, Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation (MTPC) have declared the introduction of the Mounjaro subcutaneous injection 2.5 mg / 5 mg ATEOS in Japan which represents a promising treatment alternative for type 2 diabetes.
• 22 May 2024, Mitsubishi Tanabe Pharma Corporation (MTPC), part of the Mitsubishi Chemical Group and headquartered in Chuo-ku, Osaka, Japan, announced the release of the SGLT2 inhibitor CANAGLU® OD Tablets 100 mg, to provide a new treatment option for type 2 diabetes mellitus. The CANAGLU® OD Tablets are designed to disintegrate quickly with just a slight amount of moisture, such as saliva, facilitating easier ingestion. This feature is particularly beneficial for individuals with type 2 diabetes requiring continuous medication, as it enhances convenience and adherence to treatment.

Key Questions Answered in This Report:

• How has the Japan diabetes market performed so far, and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan diabetes market?
• What is the breakup of the Japan diabetes market on the basis of segment?
• What are the various stages in the value chain of the Japan diabetes market?
• What are the key driving factors and challenges in the Japan diabetes market?
• What is the structure of the Japan diabetes market, and who are the key players?
• What is the degree of competition in the Japan diabetes market?

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Japan diabetes market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the Japan diabetes market.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Japan diabetes industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.